In addition, imaging studies showed that radiolabeled IGF-I could identify HER2-positive breast cancer cells that were resistant to trastuzumab and overexpressed IGF-IR [15], suggesting that IGF-IR expression may be used as a proxy to identify resistant cancers. Here, ERBB2 is linked to breast carcinoma.